Galnon
Galnon
|
(IUPAC) ime
|
9H-fluoren-9-ylmethyl N-[(2S)-1-([(2S)-6-amino-1-[(4-methyl-2-oxochromen-7- yl)amino]-1-oxohexan-2-yl]amino)-3-cyclohexyl-1-oxopropan-2-yl]carbamate
|
Klinički podaci
|
Identifikatori
|
CAS broj
|
475115-35-6
|
ATC kod
|
?
|
PubChem[1][2]
|
5311268
|
ChEMBL[3]
|
CHEMBL451433 Y
|
Hemijski podaci
|
Formula
|
C40H46N4O6
|
Mol. masa
|
678.815
|
SMILES
|
eMolekuli & PubHem
|
InChI |
InChI=1S/C40H46N4O6/c1-25-21-37(45)50-36-23-27(18-19-28(25)36)42-38(46)34(17-9-10-20-41)43-39(47)35(22-26-11-3-2-4-12-26)44-40(48)49-24-33-31-15-7-5-13-29(31)30-14-6-8-16-32(30)33/h5-8,13-16,18-19,21,23,26,33-35H,2-4,9-12,17,20,22,24,41H2,1H3,(H,42,46)(H,43,47)(H,44,48)/t34-,35-/m0/s1 Y Key: IKNOZZKXIDSTRN-UHFFFAOYSA-N Y |
|
Farmakoinformacioni podaci
|
Trudnoća
|
?
|
Pravni status
|
|
Galnon je lek koji deluje kao selektivni, ne-peptidni agonist galaninskog receptora receptora.[4][5] Za njega je pokazano u životinjskim ispitivanjima da ima antiepileptičko, anksiolitičko, anoreksno i amnesivno dejstvo.[6][7][8][9][10]
Literatura
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
- ↑ Saar K, Mazarati AM, Mahlapuu R, Hallnemo G, Soomets U, Kilk K, Hellberg S, Pooga M, Tolf BR, Shi TS, Hökfelt T, Wasterlain C, Bartfai T, Langel U (May 2002). „Anticonvulsant activity of a nonpeptide galanin receptor agonist”. Proceedings of the National Academy of Sciences of the United States of America 99 (10): 7136–41. DOI:10.1073/pnas.102163499. PMC 124541. PMID 12011470.
- ↑ Sollenberg U, Bartfai T, Langel U (June 2005). „Galnon--a low-molecular weight ligand of the galanin receptors”. Neuropeptides 39 (3): 161–3. DOI:10.1016/j.npep.2004.12.019. PMID 15944006.
- ↑ Abramov U, Florén A, Echevarria DJ, Brewer A, Manuzon H, Robinson JK, Bartfai T, Vasar E, Langel U (February 2004). „Regulation of feeding by galnon”. Neuropeptides 38 (1): 55–61. DOI:10.1016/j.npep.2004.01.001. PMID 15003717.
- ↑ Badie-Mahdavi H, Behrens MM, Rebek J, Bartfai T (June 2005). „Effect of galnon on induction of long-term potentiation in dentate gyrus of C57BL/6 mice”. Neuropeptides 39 (3): 249–51. DOI:10.1016/j.npep.2004.12.010. PMID 15944018.
- ↑ Rajarao SJ, Platt B, Sukoff SJ, Lin Q, Bender CN, Nieuwenhuijsen BW, Ring RH, Schechter LE, Rosenzweig-Lipson S, Beyer CE (October 2007). „Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon”. Neuropeptides 41 (5): 307–20. DOI:10.1016/j.npep.2007.05.001. PMID 17637475.
- ↑ Kozlovsky N, Matar MA, Kaplan Z, Zohar J, Cohen H (March 2009). „The role of the galaninergic system in modulating stress-related responses in an animal model of posttraumatic stress disorder”. Biological Psychiatry 65 (5): 383–91. DOI:10.1016/j.biopsych.2008.10.034. PMID 19095221.
- ↑ Narasimhaiah R, Kamens HM, Picciotto MR (May 2009). „Effects of galanin on cocaine-mediated conditioned place preference and ERK signaling in mice”. Psychopharmacology 204 (1): 95–102. DOI:10.1007/s00213-008-1438-7. PMC 2872184. PMID 19099295.
Spoljašnje veze
Šablon:Neuropeptidni ligandi
|
|